Zenas BioPharma Q1 net loss $81M; obexelimab BLA on track

Zenas BioPharma, Inc.

Net loss $81.0M in Q1 2026 vs $33.6M in Q1 2025; R&D expenses rose to $60.4M.
Cash and investments $718.5M as of Mar 31; raised $419M year-to-date from offerings and debt facility.
Obexelimab BLA for IgG4-RD expected this quarter; EMA filing H2 2026; INDIGO data at EULAR June 4.
Phase 2 SunStone SLE trial enrollment completed; topline results expected Q4 2026.
Director Tomas Kiselak did not stand for re-election; board size reduced by one.

item 2.02item 5.02item 5.07item 9.01

Source: SEC EDGAR

accession 0001104659-26-059700

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.